Home » Topics » BioWorld Science

BioWorld Science
RSS

Topline data presented from phase III KEEPsAKE studies of risankizumab

Jan. 8, 2021

First patient dosed in phase I study of Replimune's third clinical candidate, RP-3

Jan. 8, 2021

Dosing initiates in phase IIa study of MET-409 plus empagliflozin in patients with T2DM and NASH

Jan. 8, 2021

Activating NK cells without interleukins

Jan. 8, 2021

Vir initiates phase I trial of HIV T-cell vaccine VIR-1111

Jan. 8, 2021

FDA clears IND for phase I trial of PRGN-2012 for recurrent respiratory papillomatosis

Jan. 8, 2021

HDGF is a therapeutic target in hepatitis

Jan. 8, 2021

Extension study results of patisiran in transthyretin-related amyloid polyneuropathy presented

Jan. 8, 2021

ApoE multitasks for regulating brain lipids

Jan. 8, 2021

Sanofi selects NK cell engager IPH-6101 as drug candidate

Jan. 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...